Arcutis Biotherapeutics ARQT 深 滬
等待開盤 02-07 09:30:00 美东时间
27.32
+1.250
+4.79%
華盛通- 最 高27.50
- 今 開26.50
- 成交量 136.30万股
- 最 低 26.405
- 昨 收 26.07
- 總市值 33.46亿
- 52周最高 31.77
- 市盈率 靜 --
- 換手率 1.11%
- 52周最低 11.75
- 委 比 40.81%
- 總股本 1.22亿
- 歷史最高 40.88
- 量 比 0.95
- 振 幅 4.20%
- 歷史最低 1.76
- 每 手 1
- 風險率 5.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Arcutis Biotherapeutics Announces ZORYVE Was Well Tolerated With Consistent Safety Profile In Clinical Trial Of INTEGUMENT-INFANT Phase 2 Study
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced positive topline results from the
02-02 21:12
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
A study found that ZORYVE® cream 0.05% significantly improved eczema in 58% of infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis, showing both safety and efficacy. No new safety concerns were identified over four weeks. The therapy is particularly important as atopic dermatitis affects 9.6 million U.S. children, with symptoms often starting within the first year. The company plans to submit an application for th...
02-02 13:00
美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
<p>A nationwide survey of adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis reveals concerns about side effects of topical steroids and a lack of proactive long-term treatment options. Nearly 9 in 10 are worried about steroid side effects, and nearly 8 in 10 believe their treatment focuses on reacting to flare-ups rather than preventing them. When uncontrolled, the conditions cause emotional, menta...
01-21 13:00
Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
Arcutis Biotherapeutics announced its 2026 strategic priorities: Continued strong growth of ZORYVE® (roflumilast) with net product sales expected to reach $455–$470 million. Advancing ZORYVE's indication expansion with Phase 2 trials in vitiligo and hidradenitis suppurativa. Launching the clinical development program for ARQ-234 for atopic dermatitis. Transitioning to positive cash flows to accelerate ZORYVE growth and pipeline advancement.
01-12 13:00
Arcutis Biotherapeutics Appoints Amit Munshi as New Director
Arcutis Biotherapeutics ( ($ARQT) ) has provided an update. On December 3, 2025...
2025-12-09 05:44
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
Arcutis Biotherapeutics announced the appointment of Amit Munshi to its Board of Directors and the retirement of founding Board member Bhaskar Chaudhuri, who will continue as a consultant. Frank Watanabe, CEO, expressed confidence in Munshi's expertise in financing and strategic transactions to support the company's growth, including expanding the commercialization of ZORYVE and advancing its pipeline. Keith Leonard, chairman, thanked Chaudhuri f...
2025-12-08 21:00
美股大行评级 | 美银证券下调哔哩哔哩目标价至31美元；高盛下调诺和诺德目标价至54美元
今日重点评级关注：Benchmark：维持Grupo Televisa"买入"评级，目标价从9美元升至10美元；Truist Securities：维持迪尔股份"买入"评级，目标价从609美元升至612美元
2025-12-01 14:33
Mizuho Maintains Outperform on Arcutis Biotherapeutics, Raises Price Target to $37
Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Outperform and raises the price target from $32 to $37.
2025-11-28 23:11
Arcutis Zoryve cream sNDA accepted by FDA for pediatric plaque psoriasis
The U.S. FDA has accepted a sNDA from Arcutis Biotherapeutics (ARQT) for its Zoryve (roflumilast) cream for the treatment of plaque psoriasis in children ages two to five years old. The application ha...
2025-11-17 22:05
